سعر فينتادور 25مكجم 5 باتش 2026

Fentadur 25 mcg/hr 5 transdermal patch: fentanyl transdermal patches releasing 25 micrograms per hour, pack of 5, listed in Egypt by Egyptian Pharmaceutical Trading Company; a strong opioid analgesic for severe chronic pain in opioid-tolerant patients (controlled drug).

• Adults: severe chronic pain requiring continuous long-term opioid treatment. Children from 2 years: long-term treatment of severe chronic pain in children already receiving opioid therapy.Population: Adults; opioid-tolerant children from 2 yearsHexal AG / Sandoz (manufacturer-published Fachinformation)

• Most frequent in pooled clinical studies (>=10%): nausea (35.7%), vomiting (23.2%), constipation (23.1%), somnolence (15.0%), dizziness (13.1%) and headache (11.8%).International label, equivalent formulation · Hexal AG / Sandoz (manufacturer-published Fachinformation)

• Hypersensitivity to fentanyl or excipients; acute or postoperative pain (dose titration impossible in short-term use, risk of life-threatening hypoventilation); severe respiratory depression.International label, equivalent formulation · Hexal AG / Sandoz (manufacturer-published Fachinformation)

• The patch contains an amount of fentanyl that can be fatal, especially to a child: keep all patches (before and after use) out of reach of children and stored securely against accidental exposure, misuse and abuse. After serious adverse reactions, monitor for at least 24 hours after patch removal because serum fentanyl falls only gradually (about 50% in 20-27 hours).International label, equivalent formulation · Hexal AG / Sandoz (manufacturer-published Fachinformation)
• Boxed warnings (US label): addiction, abuse and misuse; life-threatening respiratory depression; accidental exposure (especially children) can be fatal; neonatal opioid withdrawal syndrome with prolonged use in pregnancy; cytochrome P450 3A4 interactions; risks with concomitant benzodiazepines or other CNS depressants; exposure of the application site to heat can increase fentanyl release.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• CNS depressants (benzodiazepines and other sedatives/hypnotics, other opioids, general anaesthetics, phenothiazines, sedating antihistamines, alcohol), muscle relaxants, gabapentinoidsDisproportionate increase in CNS depression (respiratory depression, hypotension, deep sedation, coma, death); limit dose and duration and monitor closely.Hexal AG / Sandoz (manufacturer-published Fachinformation)
• MAO inhibitorsNot recommended; do not use within 14 days after stopping an MAOI (severe, unpredictable potentiation of opioid or serotonergic effects).Hexal AG / Sandoz (manufacturer-published Fachinformation)
• Serotonergic drugs (SSRIs, SNRIs, MAOIs)Increased risk of serotonin syndrome.Hexal AG / Sandoz (manufacturer-published Fachinformation)

• Insufficient data in pregnant women; animal studies showed some reproductive toxicity. Neonatal withdrawal has been reported after prolonged transdermal fentanyl use in pregnancy. Do not use in pregnancy unless clearly necessary.International label, equivalent formulation · Hexal AG / Sandoz (manufacturer-published Fachinformation)
• Fentanyl passes into breast milk and may cause sedation or respiratory depression in the infant: do not breastfeed during treatment and for at least 72 hours after patch removal.International label, equivalent formulation · Hexal AG / Sandoz (manufacturer-published Fachinformation)

• Fentanyl: Potent synthetic agonist of mu-opioid receptors in the brain and spinal cord, reducing pain perception; also causes respiratory depression and sedation.